Edward Scott, ex-ElectrifAi CEO, faces multiple civil suits alleging inflated AI claims, racial misconduct, and investor deception — now leading an undisclosed AGI startup.
Former CEO, ElectrifAi LLC (fka Opera Solutions) · Current CEO, Undisclosed Stealth AGI Startup
Primary Jurisdictions
United States — New Jersey, New York (SDNY), California (White Oak affiliation)
Investigation Period
2018–2025
Methodology
OSINT synthesis drawing from primary investigative journalism (MedCity News), verified federal court dockets (PACER/UniCourt), state court filings (NJ Superior Court), subject-originated PR material (edward-scott.com, CDO Magazine placement), and secondary aggregator sources classified by evidence tier. All adverse claims are attributed to their originating source with explicit evidence-class labeling. No unverified tip material has been elevated to factual assertion.
Key findings from the OSINT investigation. All allegations are unproven unless legally established.
Edward Scott is a private-equity-installed AI company CEO whose curated public persona — Harvard MBA, Apollo and Akamai pedigree, 'machine learning innovator' branding — stands in documented contradiction to a multi-year civil litigation record spanning investor fraud, product misrepresentation, racially abusive workplace conduct, sexual harassment cover-up, and systematic retaliation, all substantiated by named federal plaintiffs, two MedCity News investigative reports, and confirmed court dockets in SDNY and D.N.J. As of February 2025, Scott leads an unidentified stealth AGI startup with no public corporate registration and no disclosed adverse history, raising fresh concerns for prospective investors and employees.
Edward Scott is a private-equity-installed AI company executive whose documented public record stands in direct and material contradiction to the 'machine learning innovator' and 'AI turnaround leader' persona he has cultivated across a network of personal PR properties. Between 2018 and early 2025, Scott served as CEO of ElectrifAi LLC (formerly Opera Solutions OPCO LLC), a New Jersey-based artificial intelligence company installed by San Francisco private equity firm White Oak Global Advisors following a defaulted loan. During that period, Scott became the named defendant or co-defendant in at least four civil proceedings filed across two federal districts and one state court, with allegations spanning investor fraud, product misrepresentation, racially abusive workplace conduct targeting employees of Indian descent, sexual harassment cover-up, and systematic retaliation against employees who raised concerns.
The product-fraud vector is particularly specific and multi-sourced: a former head of product filed a whistleblower complaint alleging ElectrifAi publicly claimed more than 1,000 ready-to-deploy machine learning models when fewer than 120 existed, and that Scott directed staff to sell non-existent products. Concurrent investigative reporting by MedCity News documented alleged revenue inflation to investors and reseller partners, the marketing of an AI diagnostic product with an inadequate clinical validation basis, and a workplace culture of racial hostility and retaliation. As of February 2025, Scott has departed ElectrifAi and assumed the CEO role at an undisclosed stealth-mode AGI startup whose corporate identity has not been publicly registered or disclosed — a transition covered in positive industry media with no reference to the pending civil record, raising substantive opacity concerns for prospective investors and employees who may be unaware of that history.
Civil Proceedings Identified
Four confirmed and one flagged civil proceedings across SDNY, D.N.J., and NJ Superior Court naming Scott and/or ElectrifAi as defendants. Spanning 2019–2023.
Revenue Misrepresentation Gap (Alleged)
Alleged gap between Scott's $50M revenue representation to prospects and the ~$19M internal management figure for FY2020, per McGowan complaint as reported by MedCity News.
ML Model Count Discrepancy (Alleged)
Alleged gap between 1,000+ ML models publicly claimed by ElectrifAi and fewer than 120 that actually existed, per McGowan complaint as reported by MedCity News.
Risk Classification
Based on AML exposure, offshore structures & PEP associations
Insufficient publicly available information on family members, spousal affiliations, or familial business connections has been identified in any reviewed primary or secondary source. No family member has been named as a co-defendant, business associate, or beneficial owner in any identified court filing or corporate registry.
Scott's professional network relevant to this investigation is defined by institutional rather than familial relationships: White Oak Global Advisors as appointing PE backer, the named plaintiffs in civil proceedings as adversarial counterparties, and the undisclosed co-founders or investors in the February 2025 stealth AGI venture whose identities have not been publicly confirmed.
ElectrifAi LLC (fka Opera Solutions OPCO LLC) — CEO, 2018–2025
Scott was appointed CEO of Opera Solutions in late 2018 after White Oak Global Advisors took control of the company following a defaulted loan. He oversaw the rebranding to ElectrifAi and led the company until approximately February 2025. During his tenure, the company became the subject of multiple civil lawsuits and two MedCity News investigative reports alleging investor fraud, product misrepresentation, racial harassment, and retaliation. [SOURCE: MedCity News, September 2020 and September 2021 — VERIFIED PUBLIC]
Undisclosed Stealth AGI Startup — CEO, February 2025–Present
As of February 2025, Scott transitioned to the CEO role at an early-stage AGI company described as stealth-mode. No corporate name, registered address, state incorporation filing, or SEC Form D has been publicly identified. CDO Magazine reported the move as a straightforward career milestone with no reference to the ElectrifAi adverse record. The gap between this positive coverage and Scott's civil litigation history constitutes a documented reputation-management artifact. [SOURCE: CDO Magazine, February 2025 — REPORTED; Corporate registration: Insufficient publicly available information — INFERRED opacity concern]
White Oak Global Advisors LLC — Managing Director (prior to 2018)
Scott served as Managing Director at White Oak Global Advisors, a San Francisco-based private equity firm, prior to his appointment as CEO of Opera Solutions. White Oak's role in installing Scott as CEO following its debt-acquisition of Opera Solutions is documented in MedCity News reporting. White Oak declined comment to MedCity News. White Oak has not been named as a defendant in any identified civil proceeding arising from the ElectrifAi period. [SOURCE: MedCity News, September 2020 — VERIFIED PUBLIC; White Oak response: declined comment — VERIFIED PUBLIC]
Apollo Global Management — Prior Role
Scott's personal website (edward-scott.com) lists a prior role at Apollo Global Management, a major global private equity firm. The specific title, dates, and scope of this engagement have not been independently verified from a source other than Scott's own PR properties. [SOURCE: edward-scott.com — SUBJECT-ORIGINATED; Independent verification: Insufficient publicly available information]
Akamai Technologies — Prior Role
Scott's personal website also lists a prior engagement at Akamai Technologies, a content delivery and cloud services company. As with the Apollo claim, the specific title and dates have not been independently verified from a non-subject source. [SOURCE: edward-scott.com — SUBJECT-ORIGINATED; Independent verification: Insufficient publicly available information]
PulmoAi — AI Diagnostic Product (ElectrifAi sub-product)
Under Scott's leadership, ElectrifAi developed and marketed PulmoAi as a COVID-19 diagnostic solution for emergency rooms. MedCity News reported that the model was trained on as few as 10 images of COVID-19 patients — a sample size described by the outlet as far too small to build a working algorithm. The company claimed Catholic Health Services of Long Island would implement it; neither the hospital nor the company confirmed it was ever deployed. No FDA clearance, 510(k) submission, or ClinicalTrials.gov registration for PulmoAi has been confirmed from publicly available regulatory databases. [SOURCE: MedCity News, September 2020 — VERIFIED PUBLIC; FDA status: Insufficient publicly available information]
Click an event for full details
Select a milestone to view details
Scott's personal website lists a role at Apollo Global Management. Specific title, dates, and scope are unverified from any independent source. [SUBJECT-ORIGINATED]
Career Overview
Confirmed and flagged entity relationships in the Edward Scott / ElectrifAi network — classified by evidence tier
No Russian entity connections identified
No Russian-jurisdiction corporate connection has been established. [Insufficient publicly available information]
No OFAC/sanctions nexus identified
No sanctions or OFAC-listed counterparty has been identified in Scott's confirmed network.
Section populated to maintain schema integrity
This field is not applicable to the Edward Scott profile.
No European entity connections identified
All confirmed entities are incorporated and operating in the United States. [Insufficient publicly available information]
No offshore European structure identified
No Cyprus, BVI, Luxembourg, or other European offshore vehicle has been found in connection with Scott or ElectrifAi.
Section populated to maintain schema integrity
This field is not applicable to the Edward Scott profile as currently documented.
Tap an entity to view details · Drag slider to explore changes over time
Scott appointed CEO; White Oak takeover
Select an entity
Click any node to view entity details, jurisdiction, and ownership notes.
Interactive visualization of alleged shell company operators and their network of liquidated entities. Click an operator to highlight connections.
2
Total Director Roles
0
Total Founder Roles
1 of 3 confirmed entities rebranded/wound down
Liquidation Rate
$19M FY2020 actual revenue (internal) vs. $40–50M represented externally [ALLEGED — McGowan complaint per MedCity News]
Reported Financial Activity
Undisclosed New Entity
Identity of stealth AGI startup is publicly unknown
No state incorporation, SEC Form D, or public registration identified as of investigation date
PE Appointment Mechanism
Scott installed as CEO via White Oak's defaulted-loan takeover
Governance accountability chain from PE backer to CEO misconduct period not publicly documented in board resolutions
No Adverse Disclosure to New Investors
CDO Magazine Feb 2025 coverage omitted all adverse record
Prospective investors in stealth AGI startup face undisclosed counterparty risk from Scott's civil litigation history [INFERRED]
Key Concern
The primary ownership-structure concern is not a layered offshore shell architecture — none has been identified — but rather the opacity created by the February 2025 transition to an unregistered, unnamed stealth AGI startup, which insulates Scott's new investor and employee counterparties from awareness of his documented civil litigation record. This opacity is analytically significant precisely because it is not structurally complex: it relies on the commercial convention of 'stealth mode' to achieve the same information asymmetry that offshore structures produce in other subject profiles. [INFERRED — analytical conclusion from documented evidence; not a stated fact]
Edward Scott does not meet the definition of a Politically Exposed Person (PEP) under standard FATF, EU 4AMLD, or US BSA frameworks. No current or former government role, public office, state enterprise directorship, or senior political party position has been identified. Scott's institutional affiliations are entirely private-sector: White Oak Global Advisors (PE), Apollo Global Management (PE — self-reported), Akamai Technologies (tech — self-reported), Opera Solutions / ElectrifAi (AI company). No PEP designation applies.
No OFAC designation, EU sanctions listing, UN Security Council listing, UK Office of Financial Sanctions Implementation (OFSI) entry, or any equivalent sanctions record has been identified for Edward Scott or any confirmed entity in his network. The CMS government contract ($68M) referenced in the Kumar lawsuit is a domestic US government procurement contract, not a sanctions-relevant transaction. No sanctions adjacency has been established.
Product Misrepresentation — ML Model Count Inflation (Alleged)
According to allegations in the McGowan product-fraud complaint (filed July 2021) as reported by MedCity News, ElectrifAi publicly claimed more than 1,000 ready-to-deploy machine learning models when fewer than 120 actually existed, including some in early stages of development. Scott allegedly directed staff to 'sell them something' when products did not exist, including pitching a non-existent unemployment insurance fraud detection model to a potential customer. [ALLEGED — civil complaint per MedCity News, September 2021. Complaint text not directly retrieved via PACER as of investigation date.]
Investor and Partner Revenue Inflation (Alleged)
According to allegations in the McGowan complaint as reported by MedCity News, Scott told prospects 'You should think of ElectrifAi as a $50 million company' when internal management meetings reflected approximately $19 million in actual FY2020 revenue. He allegedly represented revenues of more than $40 million to a potential reseller partner CEO; that deal did not close when he could not produce an audited financial report. He also allegedly told board meetings ElectrifAi would reach at least $30 million by end of 2020. [ALLEGED — civil complaint per MedCity News, September 2021]
Racially Abusive Workplace Conduct — Multiple Named Plaintiffs (Alleged)
According to allegations in Kumar v. ElectrifAi LLC et al (SDNY 1:20-CV-06824), Scott is alleged to have said 'I got rid of all the dirty Indians and it is safe for white people at Opera again.' According to allegations in Fahey v. Scott et al (D.N.J. 2:21-cv-12484) as reported by MedCity News, Scott is further alleged to have made a more extreme racial threat against employees of Indian descent. These statements are presented as allegations made by named plaintiffs in identified federal civil proceedings — not as established facts. [ALLEGED — multiple named civil complaints; VERIFIED PUBLIC as to existence of dockets]
Sexual Harassment Cover-Up and Disability Discrimination Retaliation (Alleged)
According to allegations in Fahey v. Scott et al (D.N.J. 2:21-cv-12484), ElectrifAi's late Chief Information Officer allegedly made harassing late-night calls to Debra Fahey of a sexual nature. Leadership allegedly berated Fahey for reporting the harassment rather than investigating. Fahey's attorney, Brian Graffeo, stated her termination constituted disability discrimination and retaliation for complaints regarding discrimination, harassment, and hostile work environment at ElectrifAi and White Oak. [ALLEGED — civil complaint; attorney statement per MedCity News, September 2021]
Hospital Billing Manipulation — Contract Retention Scheme (Alleged)
A former executive with knowledge of company practices alleged to MedCity News that employees were instructed to trickle out hospital billing charge findings slowly and make reports appear to show higher charges, so that hospitals would renew contracts with ElectrifAi. This allegation originates from an unidentified former executive and has not been corroborated by a court filing. [ALLEGED — unidentified former executive per MedCity News, September 2021; source classification: REPORTED with unverified element]
PulmoAi Clinical Validation — COVID-19 Diagnostic Marketing Without Adequate Basis (Alleged)
MedCity News reported that ElectrifAi's PulmoAi model was trained on as few as 10 images of COVID-19 patients — a sample size the outlet described as far too small to build a working algorithm. The company marketed PulmoAi as a COVID-19 emergency room diagnostic solution, claiming Catholic Health Services of Long Island would implement it. Neither the hospital nor the company confirmed the product was ever used. No FDA clearance for PulmoAi has been confirmed. [ALLEGED / REPORTED — MedCity News, September 2020; FDA status: Insufficient publicly available information]
Adverse media coverage of Edward Scott is concentrated in two primary investigative reports by MedCity News (September 2020 and September 2021), supplemented by secondary aggregator profiles on LegalObserver.com and CyberCriminal.com, and by positive placement coverage in CDO Magazine (February 2025) that creates a documented PR-versus-record contradiction. The MedCity News reporting is classified as primary investigative journalism — the outlet conducted on-record interviews with named plaintiffs and attorneys, reviewed filed court documents, and made repeated (declined) interview requests to Scott. Secondary aggregator sources carry no independent evidentiary weight and are included only for SERP saturation analysis. The geographic footprint of the adverse media record is entirely domestic US, centered on New Jersey AI industry coverage.
6 identified locations · Adverse SERP footprint: multi-source, domestic US. No international adverse media identified.
Filter by Jurisdiction
6 properties — click a marker for details
2 (MedCity News)
Primary Investigative Reports
2+ (LegalObserver, CyberCriminal)
Adverse Aggregator Profiles Indexed
3+ (CDO Magazine, BillionSuccess, edward-scott.com)
Positive PR Placements Identified
Yes / No — Scott declined all requests
Right-of-Reply Offered / Accepted
Scott's documented personal brand apparatus versus the civil and investigative adverse record — a systematic image-versus-evidence contradiction
Scott's documented personal brand apparatus versus the civil and investigative adverse record — a systematic image-versus-evidence contradiction
Hover over any node to highlight its connections. The graph maps relationships between ventures, coordinated PR outlets, and targeted platforms.
CDO Magazine placement covering Scott's transition to unnamed stealth AGI startup presented exclusively as a positive career development, with no reference to four identified civil proceedings still unresolved. No evidence of proactive disclosure to new investors. [REPORTED — CDO Magazine; INFERRED — reputation management intent]
edward-scott.com maintained a curated positive narrative throughout the entire active litigation period — Harvard MBA credential, AI innovation framing, PE pedigree — with no reference to the Ramasubbu (2019), Kumar (2020), Fahey (2021), or McGowan (2021) proceedings. [SUBJECT-ORIGINATED — ongoing]
Despite two major MedCity News investigative reports and three active or newly filed civil proceedings, no on-record denial, attorney statement, or press release from Scott or ElectrifAi counsel was identified in any retrieved source. The absence of a formal denial is itself a documented data point. [VERIFIED PUBLIC — MedCity News right-of-reply record]
Each public claim cross-referenced against available OSINT evidence. Click any row to expand.
All claims are derived from publicly available OSINT sources. This table does not assert legal wrongdoing. Click any row to expand evidence and analyst notes.
Key documented events in chronological order. Drag to scroll.
Scroll or drag to explore — click any event for detailsSwipe to explore — tap any event for details
10 documented events · 2018–2025
Four-quadrant risk assessment by impact severity and likelihood of exposure.
HR Function Dismantlement During Active Misconduct Period
MedCity News reported (September 2020) that Scott forced out the head of HR and both remaining HR staff subsequently resigned, leaving Scott as the de facto sole HR authority during the same period when racial harassment and sexual harassment were allegedly occurring. This structural governance failure is not an incidental personnel matter — it removed the institutional check that would normally have intercepted the pattern of conduct alleged by five named plaintiffs. [REPORTED — MedCity News, September 2020]
Revenue Misrepresentation Across Multiple Audience Types
Alleged revenue inflation was not targeted at a single investor or partner — according to the McGowan complaint as reported by MedCity News, Scott allegedly misrepresented ElectrifAi's revenue to board meetings ($30M target), to investor prospects ($50M framing), and to a reseller partner CEO ($40M+). The multi-directional, multi-audience nature of the alleged inflation indicates a systemic practice rather than an isolated statement. [ALLEGED — McGowan complaint per MedCity News, September 2021]
Quantified Product Count Misrepresentation — Specific and Named
The ML model count allegation (1,000+ claimed vs. fewer than 120 actual) is unusually specific for a civil complaint and originates from a named insider witness — the former Head of Product — who was positioned to know the actual inventory. Specificity and insider provenance elevate the credibility weight of this allegation above generic fraud claims. [ALLEGED — McGowan complaint per MedCity News; note: complaint text not directly retrieved via PACER as of investigation date]
Employee Surveillance via Carbonite During Whistleblowing Period
MedCity News reported that ElectrifAi under Scott's leadership surveilled employees via Carbonite software. If accurate, this would indicate active monitoring of the workforce at precisely the time multiple employees were preparing or filing complaints — a pattern that, in the context of the retaliation allegations, constitutes a significant governance red flag. [REPORTED — MedCity News, September 2020; retaliation classification: ALLEGED — civil complaints]
Transition to Undisclosed Entity With No Public Adverse Disclosure
Scott's February 2025 transition to a stealth AGI startup was covered in positive trade press with no reference to four then-pending civil proceedings. No corporate registration for the new entity has been publicly identified. This creates a documented information asymmetry for new investors and employees — the structural analog of the same opacity that characterized ElectrifAi's alleged investor misrepresentation. [INFERRED — analytical conclusion; entity identity: Insufficient publicly available information]
Sustained Active PR Apparatus Throughout Litigation Escalation
Scott maintained and appears to have actively cultivated a personal brand apparatus (edward-scott.com, BillionSuccess.com placement, CDO Magazine placement) throughout the 2019–2025 litigation escalation period. The simultaneous maintenance of a 'machine learning innovator' narrative while being named defendant in three federal civil proceedings constitutes a documented image-versus-record contradiction that is the central analytical finding of this dossier. [SUBJECT-ORIGINATED — PR sources; VERIFIED PUBLIC — litigation dockets]
PulmoAi Marketing Without Confirmed Deployment or Regulatory Clearance
ElectrifAi claimed Catholic Health Services of Long Island would implement PulmoAi for COVID-19 emergency room diagnostics. Neither the hospital nor ElectrifAi confirmed the product was ever used. No FDA 510(k) clearance or ClinicalTrials.gov registration for PulmoAi has been identified in public regulatory databases. The alleged 10-image training set, if accurate, would fall dramatically short of clinical validation standards. [ALLEGED / REPORTED — MedCity News, September 2020; FDA status: Insufficient publicly available information]
Five Civil Proceedings Over Six Years — Uninterrupted Pattern
The span from the June 2019 Ramasubbu state court filing to the April 2023 Lee federal filing represents an uninterrupted four-year litigation escalation with no identified corrective regulatory intervention and no confirmed case resolution from primary source review. The absence of any remedial action — whether internal (HR reform, leadership change) or external (regulatory enforcement) — during this period is itself analytically significant. [VERIFIED PUBLIC as to docket existence; case status: Insufficient publicly available information for most proceedings]
PACER RETRIEVAL OUTSTANDING — Full complaint texts for McGowan v. ElectrifAi (docket number unconfirmed), Ramasubbu v. Opera Solutions / ElectrifAi / Scott (MID-L-004743-19), and Lee v. ElectrifAi LLC et al (2:23-cv-02239) have not been directly retrieved. Current case status — open, settled, or dismissed — for all five identified proceedings has not been confirmed from primary source review. This is the highest-priority intelligence gap and the one most directly affecting the evidentiary weight of the dossier's legal section.
STEALTH AGI STARTUP ENTITY IDENTITY UNCONFIRMED — No corporate name, state incorporation filing (NJ, DE, NY, CT, CA), SEC Form D, USPTO trademark, or patent filing identifying Scott's February 2025 AGI venture has been publicly identified. The entity's co-founders, investors, and registered address are unknown. This gap is the most operationally significant for prospective investor and employee due diligence purposes.
ELECTRIFAI FINANCIAL RECORDS NOT INDEPENDENTLY VERIFIED — No audited financial statement, SEC filing, or independent accounting record for ElectrifAi during the Scott period has been identified. The $19M actual FY2020 revenue figure derives from the McGowan complaint (via MedCity News reporting), not from an independent financial document. No audit firm or accounting engagement associated with ElectrifAi during this period has been confirmed.
PULMOAI FDA REGULATORY STATUS UNRESOLVED — No FDA 510(k) clearance database entry, FDA warning letter, MedWatch adverse event report, or ClinicalTrials.gov registration for PulmoAi or ElectrifAi has been confirmed. The regulatory status of PulmoAi as a marketed medical device AI product remains officially unresolved from publicly available regulatory databases.
WHITE OAK GOVERNANCE ACCOUNTABILITY UNDOCUMENTED — The extent to which White Oak Global Advisors was aware of, or received reports about, the alleged misconduct at ElectrifAi during Scott's tenure has not been established from any retrieved source. White Oak declined comment to MedCity News. No board resolution, LP communication, fund disclosure, or Form ADV document connecting White Oak to the ElectrifAi misconduct period or the civil proceedings has been retrieved.
This investigation documents a civil litigation record and an adverse media profile for Edward Scott that are multi-source, multi-court, and internally consistent across a six-year period. The core findings — four confirmed civil proceedings naming Scott and/or ElectrifAi, two primary investigative reports by MedCity News, and a documented series of specific quantified allegations from named insider plaintiffs — constitute a substantive adverse record at the investigative journalism and civil litigation tier. No criminal charges, regulatory enforcement actions, or confirmed case resolutions have been identified as of the investigation date, and all adverse claims must be understood as allegations that remain to be proven in the appropriate legal forum. Scott declined all interview requests from MedCity News and no on-record denial from Scott or counsel has been identified in any retrieved source; this dossier accordingly presents the adverse record as documented without being able to incorporate his direct response. The most significant forward-looking concern is Scott's February 2025 transition to an undisclosed stealth AGI startup with no public adverse-record disclosure — a dynamic that replicates the information asymmetry that lies at the center of the investor fraud allegations in the ElectrifAi period. Any investor, partner, or employee engaging with Scott or his new venture without awareness of this record should treat this dossier as an essential component of counterparty due diligence, while recognizing that the allegations herein have not been adjudicated.
This report is produced for intelligence, journalistic, and due diligence purposes. All adverse claims are attributed to their originating source with explicit evidence-class labeling. Allegations derived from civil complaints are presented as unproven claims, not established facts. No claim in this report constitutes a finding of criminal liability. Edward Scott was given the opportunity to respond via multiple interview requests by MedCity News (declined). This report does not constitute legal advice. Readers should conduct independent verification before relying on any finding herein for consequential decisions.
Critical Risk · Tier D. The claims against Edward Scott span four principal risk categories: alleged investor and product fraud through systematic misrepresentation of AI capabilities and financial metrics; workplace misconduct including racially abusive conduct and sexual harassment covered by retaliation; governance failure through HR dismantlement and employee surveillance; and current opacity risk arising from his February 2025 transition to an unidentified stealth AGI startup without public disclosure of his adverse record. The pattern is substantiated across multiple named federal and state civil proceedings, two MedCity News investigative reports, and multiple whistleblower accounts, placing this subject at the high-to-critical tier of adverse media and civil litigation risk for counterparty due diligence purposes.
* This report is maintained as a living investigative record. Evidence is categorized by verification status and source type. User submissions are reviewed before inclusion.
Investigative Editor, Sanctions & Enforcement, based in Lisbon. Tracks sanctions programs, enforcement actions, export controls, and high-risk financial activity.
This report is maintained as a living investigative record. Evidence is categorized by verification status and source type. User submissions are reviewed before inclusion.
Subjects, representatives, and counsel may submit additional or amended responses at any time. The channel remains open — every submission is reviewed manually before publication.
A restricted research workspace from Investigations.org — daily lead intake from twelve monitored source categories, scored and source-linked for human review.


GTV Media Group settled SEC charges for $539M after raising $452M in unregistered offerings. Founder convicted, sentenced 30 years. Investor fraud examined.
Former Binance UK head and Eqonex CEO named in dismissed SDNY securities class action. FCA raised beneficial-ownership concerns during his dual executive tenure.
Gstaad Brokers Ltd, offshore arm of FXVC/Finteractive, faces FCA enforcement, CySEC fines, licence revocation & alleged EU solicitation via Seychelles shell.
FCA-regulated eMerchantPay's auditor resigned citing governance failures. Reynisson faces alleged cybercrime links, Panama Papers listing, and regulatory blind spots.
SEC alleges Jonathan Adam ran a $61.5M crypto Ponzi scheme via GCZ Global LLC while concealing three prior felony convictions. Asset freeze imposed. Case expanding.
27 former employees allege Lubin stripped ConsenSys AG equity in a Swiss-to-Delaware restructuring. JPMorgan named co-defendant. SEC case closed, NY suit active.
Alexander Spellane faces a CFTC fraud action alleging a $30M elderly-investor precious metals scheme, and a Palm Beach domestic-violence arrest.
Arun Kant and Leonie Hill Capital are not defendants in the Papermaster receivership alleging over USD 58M diverted. What the court record actually says.
Benjy Grinberg and Rostrum Records faced fraud claims from Wiz Khalifa over a 360 deal. Both suits settled in 2017 with no admission of wrongdoing.
Structured intelligence intake, watchlist tracking, custom alerts, and mobile access — and the means to underwrite the archive's independence.
Get Involved
We moderate comments to keep this a respectful and safe place. We have a zero-tolerance approach to user-to-user personal abuse. Please follow the house rules.
Participate in discussion, add context, and respond to this report.
* This discussion is moderated. Keep comments factual, relevant, and constructive. All submissions are reviewed before publication.
Submit verified tips, supporting evidence, or additional intelligence.
Request factual corrections or submit verifiable updates for this report.
* This discussion is moderated. Keep comments factual, relevant, and constructive. All submissions are reviewed before publication.
No comments yet. Be the first to comment!